All

What are you looking for?

All
Projects
Results
Organizations

Quick search

  • Projects supported by TA ČR
  • Excellent projects
  • Projects with the highest public support
  • Current projects

Smart search

  • That is how I find a specific +word
  • That is how I leave the -word out of the results
  • “That is how I can find the whole phrase”

Impact of Hormone Receptor Status on the Behaviour of HER2 Breast Cancer

The result's identifiers

  • Result code in IS VaVaI

    <a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F61989592%3A15110%2F20%3A73602726" target="_blank" >RIV/61989592:15110/20:73602726 - isvavai.cz</a>

  • Alternative codes found

    RIV/00216224:14110/20:00117213 RIV/00216208:11110/20:10417331 RIV/00216208:11120/20:43920757 RIV/00216208:11150/20:10417331 and 4 more

  • Result on the web

    <a href="http://iv.iiarjournals.org/content/34/6/3441.full.pdf" target="_blank" >http://iv.iiarjournals.org/content/34/6/3441.full.pdf</a>

  • DOI - Digital Object Identifier

    <a href="http://dx.doi.org/10.21873/invivo.12183" target="_blank" >10.21873/invivo.12183</a>

Alternative languages

  • Result language

    angličtina

  • Original language name

    Impact of Hormone Receptor Status on the Behaviour of HER2 Breast Cancer

  • Original language description

    Background/Aim: The study aimed to evaluate differences in the overall survival of HER2+ breast cancer patients treated with regard to their hormone receptors negativity or positivity. We evaluated a cohort of patients treated with trastuzumab in the Czech Republic. Patients and Methods: The present study is a retrospective analysis of patients whose data were recorded in a nationwide non-interventional, post-authorisation database BREAST. After propensity score matching of data, the cohort included 4,532 patients. Results: A significant difference in overall survival (OS) of the entire cohort was found between patients with and without hormone dependence. The OS was significantly higher in the group of patients with hormone receptor-positive (HR+) tumours in the following cohorts: patients treated with neoadjuvant therapy, patients with advanced disease, G2 tumours, stage III and IV and in patients with stage II and III of G2 tumours. Conclusion: Increased OS rates were found in several subgroups of patients with HR+/HER2+ tumours compared to those with HR/HER2+ tumours. Better outcomes of HR+/HER2+ patients were only observed in the first four/five years of follow-up, and the differences disappeared over time.

  • Czech name

  • Czech description

Classification

  • Type

    J<sub>imp</sub> - Article in a specialist periodical, which is included in the Web of Science database

  • CEP classification

  • OECD FORD branch

    30204 - Oncology

Result continuities

  • Project

  • Continuities

    I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace

Others

  • Publication year

    2020

  • Confidentiality

    S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Data specific for result type

  • Name of the periodical

    IN VIVO

  • ISSN

    0258-851X

  • e-ISSN

  • Volume of the periodical

    34

  • Issue of the periodical within the volume

    6

  • Country of publishing house

    GR - GREECE

  • Number of pages

    9

  • Pages from-to

    3441-3449

  • UT code for WoS article

    000587929100043

  • EID of the result in the Scopus database

    2-s2.0-85095589011